Evaluation of the effect of @entity16826 exposure on outcomes in kidney transplant XXXX .

@entity1 @entity9472 @entity82 @entity1071 @entity16826 @entity205 @entity281 @entity194
@entity16826 fixed-dose regimens attained better kidney function and comparable efficacy to @entity205 ( @entity9472 ) in kidney transplant @entity1 , albeit with increased risks of certain adverse events. This post-hoc analysis evaluated whether a @entity1 subgroup with an acceptable risk-benefit profile could be identified. @entity16826 exposure was a statistically significant predictor of serious @entity281 rate. One-hundred and eighty six kidney transplant @entity1 were re-categorized to above-median (AME) or below-median (BME) exposure groups. The 6-month biopsy-proven acute rejection rates in AME, BME and @entity9472 groups were 7.8%, 15.7% and 17.7%, respectively. Measured glomerular filtration rate was higher in AME and BME groups versus @entity9472 (61.2 and 67.9 vs. 53.9   mL/min) at Month 12. Fewer @entity1 developed @entity82 and @entity194 (IF/TA) at Month 12 in AME (20.5%) and BME (27.8%) groups versus @entity9472 (48.3%). @entity281 occurred more frequently in the AME group (53.0%) than in BME (28.4%) or @entity9472 (25.5%) groups. @entity1071 ( @entity1071 ) only occurred in the AME group. In kidney transplant @entity1 , the BME group preserved the clinical advantage of comparable acute rejection rates, improved renal function and a lower incidence of IF/TA versus @entity9472 , and with similar rates of serious @entity281 and no @entity1071 .
